Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 17INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

HER2 Positive Breast Cancer 1

Interventions

Exercise 16Standard of Care 10Control Groups 9Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 6Radiotherapy 6Endoscopic Mucosal Resection 6Drug Therapy 6Blood Specimen Collection 6Indocyanine Green 5anlotinib 4Metformin 4Magnetic Resonance Spectroscopy 4Laparoscopy 4Fluorouracil 4Cisplatin 4apatinib 3Vitamin D 3Ultrasonography 3Therapeutics 3Sentinel Lymph Node Biopsy 3Saline Solution 3Radiofrequency Ablation 3Quality of Life 3Proton Therapy 3Preoperative Exercise 3Methylene Blue 3Mammography 3Magnetic Resonance Imaging 3Hematologic Tests 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER_GOV × Trastuzumab × Clear all
NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡